Navigation Links
AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
Date:10/16/2007

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins. "The identification of these lead molecules and the filing of this patent constitute major milestones in the Company's goal to develop orally active anti-cancer drugs," said Dr. Richard Salvador, President and CEO, and the former global head of Preclinical Development at Hoffmann La Roche, Inc. He further stated that, "the work embodied in this patent establishes the 'drugability' of the Id proteins as targets allowing the Company to move forward with the preclinical work required to bring these molecules into the clinic."

According to Dr. William Garland, VP & Head of R&D, "both the in vitro and in vivo studies indicate that our small molecule inhibitors of the Id proteins will block angiogenesis and malignant transformation of cells responsible for tumor growth in man, and are likely to be orally active." Further, "inhibition of the Id proteins by these small molecules is unlikely to cause serious adverse effects in patients since they are not known to be required for the normal function of cells of the body. Their only function, with minor exceptions, is to promote blood vessel formation into tumors."

AngioGenex is currently testing a companion diagnostic that detects low levels of the Id proteins in serum. This diagnostic was developed in collaboration with BioCheck, Inc. of Foster City, California. Preliminary clinical results suggest that it has the potential to detect the presence of Id proteins at an early stage of tumor development allowing early medical intervention; it may also be useful to either follow the course of therapy or to determine whether there is a recurrence of disease.

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes o
'/>"/>

SOURCE AngioGenex Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
(Date:7/28/2014)... -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) ... 2014 financial results on Monday, August 4, 2014, after ... announcement, members of the management team will host a ... a general corporate update at 4:30 p.m. EDT (1:30 ... as follows: Monday, August 4 1:30 ...
(Date:7/25/2014)... 25, 2014  In today,s marketplace, launching multiple products ... - as is managing a portfolio of products in ... possible - or even preferable - to pool resources ... you combine resources and activities, and what marketing and ... are just a few of the dilemmas facing pharmaceutical ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... , SAN DIEGO, Nov. 18 Rules-Based ... biomarker alliance and services agreement with Covance Inc. (NYSE: ... with a powerful combination of biomarker technologies and services for ... will use RBM as its exclusive third-party provider of multiplexed ...
... , NASHVILLE, Tenn., Nov. 17 Emdeon (NYSE: ... cycle management solutions, today announced that it will participate in the ... 1 to 2, 2009 in New York. , The "fireside chat", ... time on Tuesday, December 1, 2009. A live audio webcast ...
Cached Medicine Technology:Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 2Rules-Based Medicine Forms Biomarker Alliance With Covance Inc. 3
(Date:7/28/2014)... St. Jude Children’s Research Hospital has ... Defense Employer Support Freedom Award from the Employer Support of ... The award is the highest honor given by the U.S. ... serve in the National Guard and Reserve. , “We deeply ... contributions to the St. Jude mission and to our country,” ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... the majority of professionals engaged in the field ... the Transplantation and Immunology Research Network ... and immunology research. As modern organ transplantation continues ... network that could provide more opportunities for physicians, ...
(Date:7/28/2014)... BEER-SHEVA, ISRAEL, July 28, 2014...Mothers who live near ... weights, according to a new study, "Green Spaces ... Occupational and Environmental Medicine . , A ... Ben-Gurion University of the Negev (BGU), evaluated nearly ... cohort in Tel Aviv, Israel to determine the ...
(Date:7/28/2014)... into improving treatment for patients with one of the ... funding boost. , Chronic obstructive pulmonary disease (COPD) is ... breathing difficulties due to long-term damage to the lungs. ... 10 per cent of all hospital admissions in the ... to hospital after they are discharged. , ...
(Date:7/28/2014)... findings made possible by a test developed at University ... (CU School of Pharmacy), AURORA, Colo (July 28, 2014) ... Colorado Antiviral Pharmacology Laboratory at the CU School of ... drug called Truvada (a combination of tenofovir/emtricitabine), which is ... A study presented during the AIDS 2014 Conference and ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2
... powerful therapy to prevent recurrence among certain follicular lymphoma patients, ... the University of Pennsylvania School of Medicine. The new findings ... by a specific protein that may be present in up ... receive a vaccine made from their own tumor cells, disease-free ...
... 2010) The next generation of drug therapies ... lymphoma are evolving as researchers continue to better ... presented today at the 52nd Annual Meeting of ... options for the standard treatment of advanced asymptomatic ...
... remove the resulting excess iron remains the best approach ... patients with sickle cell anemia, according to a preliminary ... Children,s Research Hospital. The study compared the efficacy ... iron overload caused by chronic transfusion therapy. The transfusions ...
... by the National Institute of Allergy and Infectious Diseases ... issued comprehensive U.S. guidelines to assist health care professionals ... people with the disease. The Guidelines for ... United States: Report of the NIAID-sponsored Expert Panel, developed ...
... Lesbian, gay and bisexual (LGB) adolescents are about 40 ... by school authorities, police and the courts, according to ... January 2011 issue of the journal Pediatrics , ... of LGB youth nationwide. "We found that ...
... FRIDAY, Dec. 3 (HealthDay News) -- Although winter hasn,t even ... officials said Friday. In fact, Georgia is seeing a ... the state calling it a regional outbreak. The Georgia cases ... the rest of the country once flu season really gets ...
Cached Medicine News:Health News:Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years 2Health News:Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years 3Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 2Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 3Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 4Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 5Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 6Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 7Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 8Health News:New standards of care and novel treatment options for several forms of lymphoma unveiled 9Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 2Health News:2 studies provide insight into stroke risk and prevention in young sickle cell anemia patients 3Health News:NIH-sponsored panel issues comprehensive US food allergy guidelines 2Health News:NIH-sponsored panel issues comprehensive US food allergy guidelines 3Health News:Lesbian, gay and bisexual teens singled out for punishment 2Health News:Outbreaks Signal Another Flu Season, CDC Says 2Health News:Outbreaks Signal Another Flu Season, CDC Says 3
The FastPack system is a state of the art, lab quality immunoassay system designed for rapid results. The FastPack system delivers lab-quality sensitivity at a fraction of the cost of laboratory....
... When you need quick, accurate, convenient, and ... compact VITROS DT60 II Chemistry System. This ... and back-up laboratory testing requirements. And it ... -- better patient outcomes, reduced overall costs, ...
... In an effort to improve on ... hormones, toxicology, abused drugs, and immunosuppressants ... 1991 which incorporates random access capabilities. ... has undergone several important changes in ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: